Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Pathway-Directed Therapy in Multiple Myeloma

1 Apr 2021

Abstract excerpt

Multiple Myeloma (MM) is a malignant plasma cell disorder with an unmet medical need, in particular for relapsed and refractory patients. Molecules within deregulated signaling pathways, including the RAS/RAF/MEK/ERK, but also the PI3K/AKT-pathway belong to the most promising evolving therapeutic targets. Rationally derived compounds hold great therapeutic promise to target tumor-specific abnormalities rather...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Melanoma and MAPK Pathways
Share to Multiple Myeloma Research and Treatments
Share to Protein Degradation and Inhibitors

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Source

Identifiers

PMID: 33916289
DOI: 10.3390/cancers13071668

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 23 Oct 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Pathway-Directed Therapy in Multiple MyelomaPMID 33916289Read ↗

Phosphoinositide Protein Kinase PDPK1 Is a Crucial Cell Signaling Mediator in Multiple MyelomaSemantic proximity Read ↗

Pan-Raf co-operates with PI3K-dependent signalling and critically contributes to myeloma cell survival independently of mutated RAS.Semantic proximity Read ↗

The Landscape of Signaling Pathways and Proteasome Inhibitors Combinations in Multiple MyelomaSemantic proximity Read ↗

Multiple Myeloma and Precursor Plasma Cell Disorders: From Emerging Driver Mutations to Current and Future Therapeutic StrategiesSemantic proximity Read ↗

Combined targeting of MEK/MAPK and PI3K/Akt signalling in multiple myeloma.Semantic proximity Read ↗

Molecular signaling in multiple myeloma: association of RAS/RAF mutations and MEK/ERK pathway activationSemantic proximity Read ↗

Overexpression of RKIP and its cross-talk with several regulatory gene products in multiple myelomaSemantic proximity Read ↗

[Towards precision medicine in myeloma: new evidence and challenges].Semantic proximity Read ↗

Multiple myeloma.Semantic proximity Read ↗

Advances in the pathogenesis and diagnosis of multiple myeloma.Semantic proximity Read ↗

Targeted therapy of multiple myeloma: the changing paradigm at the beginning of the new millennium.Semantic proximity Read ↗

Advances in the molecular characterization of multiple myeloma and mechanism of therapeutic resistanceSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.